|
US7550143B2
(en)
|
2005-04-06 |
2009-06-23 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7666400B2
(en)
*
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
|
EP2295450B1
(en)
|
2000-09-29 |
2015-01-28 |
Merck Sharp & Dohme Corp. |
Pegylated interleukin-10
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
US7906118B2
(en)
|
2005-04-06 |
2011-03-15 |
Ibc Pharmaceuticals, Inc. |
Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8652484B2
(en)
|
2004-02-13 |
2014-02-18 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US20110020273A1
(en)
*
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
|
US20110064754A1
(en)
*
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
US8034352B2
(en)
*
|
2005-04-06 |
2011-10-11 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8491914B2
(en)
|
2004-02-13 |
2013-07-23 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8562988B2
(en)
*
|
2005-10-19 |
2013-10-22 |
Ibc Pharmaceuticals, Inc. |
Strategies for improved cancer vaccines
|
|
US8551480B2
(en)
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8435539B2
(en)
*
|
2004-02-13 |
2013-05-07 |
Immunomedics, Inc. |
Delivery system for cytotoxic drugs by bispecific antibody pretargeting
|
|
US8003111B2
(en)
*
|
2005-04-06 |
2011-08-23 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
ES2665422T3
(es)
*
|
2005-03-03 |
2018-04-25 |
Immunomedics Inc. |
Anticuerpos L243 humanizados
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
US8481041B2
(en)
|
2005-04-06 |
2013-07-09 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US9623115B2
(en)
|
2005-04-06 |
2017-04-18 |
Ibc Pharmaceuticals, Inc. |
Dock-and-Lock (DNL) Complexes for Disease Therapy
|
|
CA2604032C
(en)
*
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
US8067006B2
(en)
|
2005-04-06 |
2011-11-29 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US8158129B2
(en)
|
2005-04-06 |
2012-04-17 |
Ibc Pharmaceuticals, Inc. |
Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
|
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US9862770B2
(en)
|
2005-10-19 |
2018-01-09 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US20100226884A1
(en)
*
|
2009-01-20 |
2010-09-09 |
Immunomedics, Inc. |
Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
|
|
WO2012024223A2
(en)
*
|
2010-08-17 |
2012-02-23 |
Immunomedics, Inc. |
Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
|
|
AU2007343610C1
(en)
*
|
2007-01-17 |
2013-11-07 |
Immunomedics, Inc. |
Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
|
|
US20100268055A1
(en)
*
|
2007-07-19 |
2010-10-21 |
Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University |
Self-Anchoring MEMS Intrafascicular Neural Electrode
|
|
JP2010536341A
(ja)
*
|
2007-08-15 |
2010-12-02 |
アムニクス， インコーポレイテッド |
生物学的に活性なポリペプチドの特性を改変するための組成物および方法
|
|
US9272029B2
(en)
|
2009-03-26 |
2016-03-01 |
Ibc Pharmaceuticals, Inc. |
Interferon lambada-antibody complexes
|
|
CN102186499B
(zh)
*
|
2008-08-20 |
2015-05-20 |
Ibc医药公司 |
用于癌症治疗的对接和锁定(dnl)疫苗
|
|
ES2655364T3
(es)
|
2008-12-17 |
2018-02-19 |
Merck Sharp & Dohme Corp. |
Producción de IL-10 mono- y dipegilada y sus usos
|
|
US8703717B2
(en)
*
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
ES2610356T3
(es)
|
2009-02-03 |
2017-04-27 |
Amunix Operating Inc. |
Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
|
|
US8680050B2
(en)
*
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
WO2010144508A1
(en)
*
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
US9849188B2
(en)
|
2009-06-08 |
2017-12-26 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
CN102596235A
(zh)
*
|
2009-08-31 |
2012-07-18 |
免疫医疗公司 |
显示有效细胞毒活性的包含豹蛙酶(rap)的免疫毒素的组合物和使用方法
|
|
CA2772572A1
(en)
*
|
2009-08-31 |
2011-03-03 |
Ibc Pharmaceuticals, Inc. |
Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
IN2012DN02692A
(enExample)
*
|
2009-11-05 |
2015-09-04 |
Ct Molecular Med & Immunology |
|
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
|
CN102665757A
(zh)
*
|
2009-12-09 |
2012-09-12 |
免疫医疗公司 |
通过双特异性抗体预靶向的用于细胞毒性药物的递送系统
|
|
AU2010328136B2
(en)
*
|
2009-12-09 |
2016-02-25 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for delivery of interference RNA
|
|
EP2518078B1
(en)
*
|
2009-12-15 |
2020-05-20 |
Choe, Muhyeon |
Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers
|
|
US10822396B2
(en)
|
2009-12-15 |
2020-11-03 |
MuHyeon CHOE |
Repeat-chain for the production of dimer, multimer, multimer complex and super-complex
|
|
US8557961B2
(en)
|
2010-04-02 |
2013-10-15 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
|
CA2812442A1
(en)
*
|
2010-11-03 |
2012-05-10 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
|
|
US9140698B2
(en)
|
2011-04-06 |
2015-09-22 |
The Board Of Regents Of The University Of Texas System |
Modulating bacterial MAM polypeptides in pathogenic disease
|
|
WO2013026015A1
(en)
|
2011-08-18 |
2013-02-21 |
Dana-Farber Cancer Institute, Inc. |
Muc1 ligand traps for use in treating cancers
|
|
WO2013036130A1
(en)
|
2011-09-09 |
2013-03-14 |
Universiteit Utrecht Holding B.V. |
Broadly neutralizing vhh against hiv-1
|
|
CA2855566A1
(en)
|
2011-12-02 |
2013-06-06 |
Ibc Pharmaceuticals, Inc. |
Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
|
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
JP6256882B2
(ja)
|
2012-02-15 |
2018-01-10 |
アムニクス オペレーティング インコーポレイテッド |
第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
|
|
JP6355563B2
(ja)
|
2012-02-27 |
2018-07-11 |
アムニクス オペレーティング インコーポレイテッド |
Ｘｔｅｎ共役組成物およびそれを製造する方法
|
|
CN104363919A
(zh)
|
2012-06-01 |
2015-02-18 |
Ibc药品公司 |
具有改进的体内稳定性、药物代谢动力学和功效的多聚体复合物
|
|
US10131712B2
(en)
|
2012-08-14 |
2018-11-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
CN104379169A
(zh)
|
2012-08-14 |
2015-02-25 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
KR101358330B1
(ko)
|
2012-09-26 |
2014-02-12 |
현대모비스 주식회사 |
차속 제어 장치, 이를 포함하는 차속 제어 시스템 및 그 제어 방법
|
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
US9789156B2
(en)
|
2013-03-11 |
2017-10-17 |
Dana-Farber Cancer Institute, Inc. |
Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics
|
|
MX2015014438A
(es)
|
2013-04-18 |
2016-05-18 |
Armo Biosciences Inc |
Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
|
|
EP3010527B1
(en)
|
2013-06-17 |
2018-08-08 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
|
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
|
US9416197B2
(en)
|
2013-11-01 |
2016-08-16 |
Ibc Pharmaceuticals, Inc. |
Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
|
|
CN120242030A
(zh)
|
2013-11-11 |
2025-07-04 |
阿尔莫生物科技股份有限公司 |
将白细胞介素-10用于治疗疾病和病症的方法
|
|
KR20160102210A
(ko)
|
2013-12-27 |
2016-08-29 |
노버스 인터내쇼날 인코포레이티드 |
에톡시화 계면활성제
|
|
KR20150080417A
(ko)
*
|
2013-12-30 |
2015-07-09 |
경희대학교 산학협력단 |
링커를 통해 연결된 동일한 표적 물질에 결합하는 항체 및 앱타머를 포함하는 집게 분자 및 이의 용도
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
EP3160504B1
(en)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
WO2016060996A2
(en)
|
2014-10-14 |
2016-04-21 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
AU2015336101A1
(en)
|
2014-10-22 |
2017-04-20 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
WO2016126615A1
(en)
|
2015-02-03 |
2016-08-11 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
AU2016228555B2
(en)
*
|
2015-03-11 |
2021-12-23 |
Nektar Therapeutics |
Conjugates of an IL-7 moiety and a polymer
|
|
AU2016252771B2
(en)
|
2015-04-22 |
2021-12-16 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
US20160361415A1
(en)
|
2015-05-28 |
2016-12-15 |
Armo Biosciences, Inc. |
Methods of Using Interleukin-10 for Treating Diseases and Disorders
|
|
US9687547B2
(en)
|
2015-05-28 |
2017-06-27 |
Immunomedics, Inc. |
T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines
|
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
EA201890423A1
(ru)
|
2015-08-03 |
2018-07-31 |
Биовератив Терапьютикс Инк. |
Слитые белки фактора ix, способы их получения и применения
|
|
KR20180038553A
(ko)
|
2015-08-25 |
2018-04-16 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
CN117659160A
(zh)
|
2015-09-11 |
2024-03-08 |
小利兰·斯坦福大学托管委员会 |
生物相关正交细胞因子/受体对
|
|
US10669338B2
(en)
|
2016-06-17 |
2020-06-02 |
Immunomedics, Inc. |
Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
|
|
WO2018027223A1
(en)
|
2016-08-05 |
2018-02-08 |
Duke University |
Camkk2 inhibitor compositions and methods of using the same
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
US10799597B2
(en)
|
2017-04-03 |
2020-10-13 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
CN107118269B
(zh)
*
|
2017-06-05 |
2020-12-01 |
北京交通大学 |
一种重组人il-24蛋白的peg修饰方法
|
|
US10584306B2
(en)
|
2017-08-11 |
2020-03-10 |
Board Of Regents Of The University Of Oklahoma |
Surfactant microemulsions
|
|
WO2019151865A1
(en)
|
2018-02-05 |
2019-08-08 |
Stichting Vu |
Inverse agonistic anti-us28 antibodies
|
|
WO2019183131A1
(en)
|
2018-03-19 |
2019-09-26 |
Bioventures, Llc |
Periostin antibodies and methods of using the same
|
|
PL3793588T3
(pl)
|
2018-05-18 |
2025-09-01 |
Bioverativ Therapeutics Inc. |
Sposoby leczenia hemofilii a
|
|
US12128099B2
(en)
|
2018-05-25 |
2024-10-29 |
Bioventures, Llc |
Myxoma virus compositions and methods of use
|
|
WO2020080941A1
(en)
|
2018-10-16 |
2020-04-23 |
Umc Utrecht Holding B.V. |
Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
|
|
US12428626B2
(en)
|
2018-11-20 |
2025-09-30 |
Bioventures, Llc |
Cells for the production of viruses and methods of using the same
|
|
US12410241B2
(en)
|
2019-07-26 |
2025-09-09 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus D68
|
|
JP2023519105A
(ja)
|
2020-02-11 |
2023-05-10 |
ヴァンダービルト ユニバーシティ |
重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
HRP20240182T1
(hr)
|
2020-03-26 |
2024-04-26 |
Vanderbilt University |
Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
|
|
WO2023056240A2
(en)
|
2021-09-28 |
2023-04-06 |
Frontaim Biomedicines, Inc. |
Multiple formats of molecular complexes
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|